1
|
Gerna G, Revello MG, Baldanti F, Percivalle E, Lilleri D. The pentameric complex of human Cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development. J Gen Virol 2017; 98:2215-2234. [PMID: 28809151 DOI: 10.1099/jgv.0.000882] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Between the 1980s and 1990s, three assays were developed for diagnosis of human cytomegalovirus (HCMV) infections: leuko (L)-antigenemia, l-viremia and l-DNAemia, detecting viral protein pp65, infectious virus and viral DNA, respectively, in circulating leukocytes Repeated initial attempts to reproduce the three assays in vitro using laboratory-adapted strains and infected cell cultures were consistently unsuccessful. Results were totally reversed when wild-type HCMV strains were used to infect either fibroblasts or endothelial cells. Careful analysis and sequencing of plaque-purified viruses from recent clinical isolates drew attention to the ULb' region of the HCMV genome. Using bacterial artificial chromosome technology, it was shown by both gain-of-function and loss-of-function experiments that UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. In addition, a number of clinical isolates passaged in human fibroblasts had lost both properties (leuko-tropism and endothelial cell-tropism) when displaying a mutation in the UL131-128 locus (referred to as UL128L). In the following years, it was shown that pUL128L was complexed with gH and gL to form the pentameric complex (PC), which is required to infect endothelial, epithelial and myeloid cells. The immune response to PC was studied extensively, particularly its humoral component, showing that the great majority of the neutralizing antibody response is directed to PC. Although anti-HCMV antibodies may act with other mechanisms than mere neutralizing activity, these findings definitely favour their protective activity, thus paving the way to the development of a potentially protective HCMV vaccine.
Collapse
Affiliation(s)
- Giuseppe Gerna
- Experimental Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | | | - Fausto Baldanti
- Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.,Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
| | - Elena Percivalle
- Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Daniele Lilleri
- Experimental Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| |
Collapse
|
2
|
Shannon KM, Cowan MJ, Matthay KK. Pediatric Bone Marrow Transplantation: Intensive Care Management. J Intensive Care Med 2016. [DOI: 10.1177/088506668700200605] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Bone marrow transplantation (BMT) has assumed in creasing importance in the treatment of bone marrow failure, hematopoietic malignancies, congenital immuno deficiencies, and solid tumors. Children undergoing BMT are at high risk for infection and hemorrhage dur ing the period of aplasia. In addition, life-threatening complications of circulatory, pulmonary, gastrointesti nal, hepatic, and renal function are common and fre quently require intensive supportive care. This review provides an overview of pediatric BMT that focuses on management problems relevant to intensive care. Thor ough pretransplantation assessment of underlying organ dysfunction is mandatory before undertaking BMT. The complications associated with preconditioning regi mens that use total body irradiation and high doses of ablative chemotherapy are described. Finally, problems involving individual organs are discussed by systems. The challenge of improving the results of BMT in the treatment of childhood malignant and hematopoietic disorders depends, in large part, on successful preven tive measures and good management of complications that occur immediately before and within the first 100 days after transplantation. As BMT is indicated for treat ment of an increasing number of diseases, more patients will require the care of intensivists familiar with trans plantation-related complications.
Collapse
Affiliation(s)
- Kevin M. Shannon
- Department of Pediatrics, University of California School of Medicine, San Francisco, CA, Clinical Investigation Center, United States Naval Hospital, Oakland, CA
| | - Morton J. Cowan
- Department of Pediatrics, University of California School of Medicine, San Francisco, CA, Clinical Investigation Center, United States Naval Hospital, Oakland, CA
| | - Katherine K. Matthay
- Department of Pediatrics, M-650, UCSF School of Medicine, San Francisco, CA 94143
| |
Collapse
|
3
|
Gangopadhyay S, Rampersaud H, Pelletier JPR, Herman L, Goldstein S, Upadhyay K. Cytomegalovirus transmission in pediatric renal transplant recipients during the window period. Pediatr Transplant 2016; 20:172-7. [PMID: 26691349 DOI: 10.1111/petr.12654] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/10/2015] [Indexed: 12/30/2022]
Abstract
We report two CMV naïve children who received deceased donor renal transplants from a CMV IgG-negative single donor. CMV IgG in both recipients and the donor were negative immediately prior to transplant. Both recipients had early recurrences of their original disease in their transplants, requiring multiple sessions of plasmapheresis. All blood products used were leukoreduced or CMV seronegative. A few days post-transplant, both recipients developed significant positive CMV viremia. Both required initiation of oral valganciclovir. Case 1 responded to oral valganciclovir only while the case 2 had a delayed response to it and hence required intravenous ganciclovir with good response. When checked retrospectively, CMV IgM in the donor was positive along with positive CMV DNA PCR from the white cells. Here we describe a very unusual scenario of CMV transmission in two pediatric renal transplant recipients from a single donor during the CMV window period.
Collapse
Affiliation(s)
- Sanhita Gangopadhyay
- Division of Nephrology, Department of Pediatrics, Shands Children's Hospital, University of Florida, Gainesville, FL, USA
| | - Howard Rampersaud
- Shands Hospital Virology Laboratory, University of Florida Health, Gainesville, FL, USA
| | - J Peter R Pelletier
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, USA
| | - Lettie Herman
- Division of Nephrology, Department of Pediatrics, Shands Children's Hospital, University of Florida, Gainesville, FL, USA
| | - Steven Goldstein
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, USA
| | - Kiran Upadhyay
- Division of Nephrology, Department of Pediatrics, Shands Children's Hospital, University of Florida, Gainesville, FL, USA
| |
Collapse
|
4
|
Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood 2015; 126:2153-61. [PMID: 26333778 DOI: 10.1182/blood-2015-05-645986] [Citation(s) in RCA: 142] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 08/06/2015] [Indexed: 11/20/2022] Open
Abstract
High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical efficacy has never been conclusively demonstrated. We report here the results of RING (Resolving Infection in Neutropenia with Granulocytes), a multicenter randomized controlled trial designed to address this question. Eligible subjects were those with neutropenia (absolute neutrophil count <500/μL) and proven/probable/presumed infection. Subjects were randomized to receive either (1) standard antimicrobial therapy or (2) standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone. The primary end point was a composite of survival plus microbial response, at 42 days after randomization. Microbial response was determined by a blinded adjudication panel. Fifty-six subjects were randomized to the granulocyte arm and 58 to the control arm. Transfused subjects received a median of 5 transfusions. Mean transfusion dose was 54.9 × 10(9) granulocytes. Overall success rates were 42% and 43% for the granulocyte and control groups, respectively (P > .99), and 49% and 41%, respectively, for subjects who received their assigned treatments (P = .64). Success rates for granulocyte and control arms did not differ within any infection type. In a post hoc analysis, subjects who received an average dose per transfusion of ≥0.6 × 10(9) granulocytes per kilogram tended to have better outcomes than those receiving a lower dose. In conclusion, there was no overall effect of granulocyte transfusion on the primary outcome, but because enrollment was half that planned, power to detect a true beneficial effect was low. RING was registered at www.clinicaltrials.gov as #NCT00627393.
Collapse
|
5
|
Slobedman B, Cao JZ, Avdic S, Webster B, McAllery S, Cheung AK, Tan JC, Abendroth A. Human cytomegalovirus latent infection and associated viral gene expression. Future Microbiol 2010; 5:883-900. [PMID: 20521934 DOI: 10.2217/fmb.10.58] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Human cytomegalovirus (HCMV) is a clinically important and ubiquitous herpesvirus. Following primary productive infection the virus is not completely eliminated from the host, but instead establishes a lifelong latent infection without detectable virus production, from where it can reactivate at a later stage to generate new infectious virus. Reactivated HCMV often results in life-threatening disease in immunocompromised individuals, particularly allogeneic stem cell and solid organ transplant recipients, where it remains one of the most difficult opportunistic pathogens that complicate the care of these patients. The ability of HCMV to establish and reactivate from latency is central to its success as a human pathogen, yet latency remains very poorly understood. This article will cover several aspects of HCMV latency, with a focus on current understanding of viral gene expression and functions during this phase of infection.
Collapse
Affiliation(s)
- Barry Slobedman
- Centre For Virus Research, Westmead Millennium Institute & University of Sydney, Westmead Millennium Institute, PO Box 412, New South Wales 2145, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Wu Y, Zou S, Cable R, Dorsey K, Tang Y, Hapip CA, Melmed R, Trouern-Trend J, Wang JH, Champion M, Fang C, Dodd R. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2009; 50:776-86. [PMID: 19912585 DOI: 10.1111/j.1537-2995.2009.02486.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Cytomegalovirus (CMV) transfusion-transmitted disease (TTD) remains a clinical concern. Universal leukoreduction has become one of the main strategies for the prevention of CMV-TTD. Through prospective clinical follow-up and testing of transfusion recipients (TRs), the risk for CMV-TTD was studied. STUDY DESIGN AND METHODS Transfused units were all leukoreduced and not prospectively screened for CMV. For TRs with negative baseline CMV testing results (CMV total antibody and DNA), all follow-up TR samples were tested for CMV total antibody and DNA, and retained linked donor serum samples were tested for CMV total antibody. In cases when CMV-TTD was suspected, donor sera were also tested for CMV DNA and selected TR samples were tested for CMV immunoglobulin M antibody. Evaluable transfusion was defined as a transfusion with TR sample(s) collected 14 to 180 days posttransfusion. RESULTS Forty-six TRs were negative for CMV at baseline. There were 1316 evaluable cellular blood transfusions to these TRs. Of 1316 evaluable cellular products, 460 (35%) were positive for CMV total antibody tested using linked donor samples. Three cases of probable CMV-TTD were found; however, there was no definitive proof from donor follow-up that they were transfusion associated. CONCLUSION Among all 46 baseline seronegative recipients and 1316 evaluable transfusions, the calculated overall CMV-TTD risk was up to 6.5% (95% confidence interval [CI], 1.0%-18.0%) in terms of TRs and up to 0.23% (95% CI, 0.06%-0.62%) in terms of non-CMV-screened leukoreduced cellular products. In summary, after universal leukoreduction, CMV-TTD, while uncommon, may still occur.
Collapse
Affiliation(s)
- Yanyun Wu
- Department of Laboratory Medicine, Yale University School of Medicine, 20 York Street, CB 459, New Haven, CT 06510-3202, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008; 112:3036-47. [PMID: 18583566 DOI: 10.1182/blood-2007-10-118372] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohematologic consequences of ABO-mismatched transplantations, or immunosuppression. Decisions concerning blood transfusions during any of these times may compromise the outcome of an otherwise successful transplantation. Years after an HPC transplantation, and even during clinical remission, recipients may continue to be immunosuppressed and may have critically important, special transfusion requirements. Without a thorough understanding of these special requirements, provision of compatible blood components may be delayed and often urgent transfusion needs prohibit appropriate consultation with the patient's transplantation specialist. To optimize the relevance of issues and communication between clinical hematologists, transplantation physicians, and transfusion medicine physicians, the data and opinions presented in this review are organized by sequence of patient presentation, namely, before, during, and after transplantation.
Collapse
|
8
|
Drew W, Roback J. Prevention of transfusion-transmitted cytomegalovirus: reactivation of the debate? Transfusion 2007; 47:1955-8. [DOI: 10.1111/j.1537-2995.2007.01494.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Roback JD, Su L, Zimring JC, Hillyer CD. Transfusion-Transmitted Cytomegalovirus: Lessons From a Murine Model. Transfus Med Rev 2007; 21:26-36. [PMID: 17174218 DOI: 10.1016/j.tmrv.2006.08.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Transfusion-transmitted cytomegalovirus (CMV) infection (TT-CMV) continues to complicate blood transfusion therapy, which can lead to severe morbidity or mortality in immunocompromised or immuno-immature recipients. The biological mechanisms that underlie TT-CMV (eg, viral latency in donor monocytes or stimulatory signals in the transfusion recipient leading to cytomegalovirus reactivation) are difficult to study in humans, but can be addressed in animal models. In this review, we discuss a mouse blood transfusion model, which can be used to investigate these issues as well as to validate methods to prevent TT-CMV in at-risk patients.
Collapse
Affiliation(s)
- John D Roback
- Department of Pathology and Laboratory Medicine, Transfusion Medicine Program, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | | | |
Collapse
|
10
|
Hedin G, Eriksson I, Kumlin U, Boman J. A lack of serologic evidence of transmission of Chlamydia pneumoniae by transfusion of buffy coat-depleted RBCs. Transfusion 2003; 43:646-50. [PMID: 12702188 DOI: 10.1046/j.1537-2995.2003.00379.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Recent studies have shown that a high percentage of blood donors harbor Chlamydia pneumoniae DNA and antigens within their PBMNCs. The aim of the present study was to investigate whether recipients of RBC transfusions who were seronegative for C. pneumoniae before transfusion showed any evidence of seroconversion after transfusion. STUDY DESIGN AND METHODS Patients who were possible recipients of RBC transfusion and negative in a screen test for IgG antibodies against C. pneumoniae at the time of blood group determination were candidates to be included in the study. The patients were contacted 3.0 to 3.5 months after the blood group determination, and those who accepted to participate agreed that another venous blood sample could be taken. RESULTS Among the patients who participated, 53 had become recipients of RBC transfusion (transfused group), and 51 later did not receive any RBC transfusion (control group). No significant change was found in IgG titer against C. pneumoniae between the first and the second sample from the same patient, in either the transfused group or the control group. CONCLUSION In our study, which was limited to 53 seronegative recipients of RBC units from seropositive donors, we found no serologic evidence that C. pneumoniae could be transmitted by RBC transfusion.
Collapse
Affiliation(s)
- Göran Hedin
- Department of Clinical Bacteriology, Huddinge University Hospital, F71, SE-141 86 Stockholm, Sweden.
| | | | | | | |
Collapse
|
11
|
Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goodnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101:2067-9. [PMID: 12406871 DOI: 10.1182/blood-2002-07-2110] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We studied the impact of donor cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte colony-stimulating factor (G-CSF)-mobilized granulocyte transfusions (GTs) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation. A cohort of 83 patients who received 2 prophylactic GTs from ABO-compatible stem cell donors following AlloPBSC transplantation was compared with a cohort of 142 patients who did not. AlloPBSC donors were eligible for granulocyte donation irrespective of their CMV serostatus. Recipients received no prophylactic therapy for CMV. Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts. Our data show that in an era of effective surveillance and preemptive therapy for CMV, AlloPBSC recipients can safely receive 2 transfusions of prophylactic G-CSF-mobilized granulocyte components from CMV-seropositive AlloPBSC donors. This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population.
Collapse
Affiliation(s)
- Ravi Vij
- Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110-1093, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Roback JD, Drew WL, Laycock ME, Todd D, Hillyer CD, Busch MP. CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 2003; 43:314-21. [PMID: 12675715 DOI: 10.1046/j.1537-2995.2003.00312.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Although serologic screening or WBC reduction of blood components can reduce the incidence of transfusion-transmitted CMV (TT-CMV) infection, 'breakthrough' cases of TT-CMV still occur and may produce serious sequelae. NAT of blood components for CMV DNA has been proposed to further reduce the risks of TT-CMV. However, large-scale studies to determine the utility of validated CMV NAT assays for donor screening have not been reported. STUDY DESIGN AND METHODS Coded whole-blood samples (n=1000) were tested for the presence of CMV DNA using two CMV PCR assays previously validated in a multicenter trial (a nested PCR assay directed at the CMV UL93 open-reading frame and the Roche Monitor assay). Corresponding plasma samples were tested in parallel for the presence of anti-CMV using other assays (Abbott CMV EIA and Fujirebio/Olympus CMV particle agglutination assays). RESULTS In total 416 and 514 of the samples tested as CMV-seropositive and -seronegative, respectively, by both antibody assays. The remaining 70 samples had discrepant serology results. Only 2 of the 1000 samples (both seropositive) had reproducibly detectable CMV DNA (positive in at least three of four replicates). CMV DNA was not reproducibly detected in seronegative samples or in samples with discrepant serology results. CONCLUSIONS Although previous investigations showed frequent detection of CMV DNA in healthy CMV-seropositive (and some seronegative) blood donors, these studies were relatively small and the performance characteristics of their assays were difficult to evaluate. In contrast, the present large cross-sectional study of US donors utilized two previously validated PCR assays and demonstrated that CMV DNA is only rarely detectable in seropositive donors. Thus, the use of CMV PCR assays with optimal performance characteristics did not increase the detection of potentially infectious blood components beyond that provided by current serologic screening assays.
Collapse
Affiliation(s)
- John D Roback
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
Among the human herpesviruses, cytomegalovirus (CMV) is the only one that has assumed significant importance in blood transfusion. Transfusion transmission of CMV (TT-CMV) to seronegative immunocompromised patients can lead to lethal CMV disease. Studies over the past 30 years have demonstrated that monocytes latently infected with CMV represent the primary vector for TT-CMV, and that TT-CMV can be largely abrogated by transfusing at-risk patients with either seronegative units or blood filtered to remove white blood cells. However, the small number of cases of breakthrough TT-CMV that follow transfusion of either seronegative or filtered blood still produce morbidity and mortality. These circumstances have motivated ongoing efforts to provide improved protection from TT-CMV, including the use of CMV DNA amplification for blood screening, and pathogen inactivation to sterilise all blood components prior to transfusion.
Collapse
Affiliation(s)
- John D Roback
- Transfusion Medicine Program, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, WMB 2307, 1639 Pierce Drive, Atlanta, GA 30322, USA.
| |
Collapse
|
14
|
Hernández-Mora MDG, Jiménez Moreno A, Guerrero e Ignacio Gadea Gironés MLF. Infección mortal por citomegalovirus en un paciente con esplenectomía y transfusión después de un traumatismo. Med Clin (Barc) 2001. [DOI: 10.1016/s0025-7753(01)71862-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Preiksaitis JK. The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening? Transfus Med Rev 2000; 14:112-36. [PMID: 10782497 DOI: 10.1016/s0887-7963(00)80003-6] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- J K Preiksaitis
- Department of Medicine, University of Alberta, Edmonton, Canada
| |
Collapse
|
16
|
SHANLEY JOHND. CYTOMEGALOVIRUS. Sex Transm Dis 2000. [DOI: 10.1016/b978-012663330-6/50011-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Abstract
Opportunistic infections are major causes of morbidity and mortality following bone marrow transplantation. Technological advances in stem cell procurement, the introduction of hematologic growth factors to speed engraftment, the development of new immunosuppressive regimens to control graft-versus-host disease (GVHD), the development of technology to perform graft engineering with removal of T lymphocytes in toto or subpopulations of T lymphocytes, the use of molecular techniques to optimize donor and recipient matching, advances in blood banking, and development of international donor registries, are among the various factors that have led to tremendous changes in transplant practices. Because of such changes in transplant practices, along with the advent of new antimicrobial agents, and development of infection control measures affecting pathogen exposure, alterations in the interplay between host and potential pathogens have occurred. Shifts in the incidence and types of opportunistic pathogens are taking place. Several historically important infectious syndromes are today well controlled; others have diminished in importance early after transplant but are more problematic at a later time; new emerging pathogens are being recognized due to selection pressures from antimicrobial usage and new hosts, such as recipients of alternate donor allogeneic transplant procedures, with even more profound and prolonged immune suppression. Such shifts and new syndromes pose continuing new challenges to the transplant clinician.
Collapse
Affiliation(s)
- J R Wingard
- Bone Marrow Transplant Program, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
| |
Collapse
|
18
|
Abstract
Transfusions of granulocytes have been used for many decades to treat serious infections in patients with sustained periods of granulocytopenia. The benefit has been limited somewhat by the technical problems of obtaining adequate doses of granulocytes from normal donors and by histocompatibility issues in alloimmunized recipients. The introduction of granulocyte colony-stimulating factor (G-CSF) as a means to induce granulocytosis in donors has rekindled interest in this therapy, particularly for the treatment of invasive fungal infections. Granulocyte yields after G-CSF stimulation are routinely 3 to 4 times higher than have been used in the past and have resulted in posttransfusion increments for more than 24 hours after transfusion. Studies in progress should help define the utility of these higher dose transfusions in patients with infections refractory to antibiotic therapy.
Collapse
Affiliation(s)
- C A Schiffer
- Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, Detroit, MI 48201, USA
| |
Collapse
|
19
|
Abstract
The Association for Professionals in Infection Control and Epidemiology, Inc, is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. This learner-paced study package is designated for 1.1 contact hours. APIC's California nursing provider number is CEP 7146. This continuing medical laboratory education activity is recognized by the American Society of Clinical Pathologists as meeting the criteria for 1 CMLE credit hour. ASCP CMLE credit hours are acceptable to meet the continuing education requirements for the ASCP Board of Registry Continuing Competence Recognition Program. (See the instructions and examination at the end of the article.)Infectious diseases represent a major cause of morbidity and mortality in immunocompromised patients. Infectious complications are often predictable and may be preventable. This article is an overview of practical considerations in the care of immunocompromised patients. Recognizing the compromised host, identifying and correcting risk factors in advance, and reducing sources of infection all play a role in prevention. Topics were chosen to include the areas of care that differ from the immune competent patient, such as diet, pet therapy, handwashing, immunizations, augmentation of host resistance, prevention of pneumonia, and antibiotic prophylaxis. National practice guidelines are cited when possible; evidence-based literature review and experience are applied to situations lacking consensus statements. Treatment decisions are made in areas for which information is often incomplete. A systematic approach to care of the immunocompromised host, tailored to the individual patient's needs, should reduce the risk of infection.
Collapse
Affiliation(s)
- G F Risi
- Missoula Medical Oncology and Infectious Disease, MT, USA
| | | |
Collapse
|
20
|
Söderberg-Nauclér C, Fish KN, Nelson JA. Growth of human cytomegalovirus in primary macrophages. Methods 1998; 16:126-38. [PMID: 9774522 DOI: 10.1006/meth.1998.0650] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Human cytomegalovirus (HCMV) is a major human pathogen that causes considerable disease among immunocompromised individuals. A primary infection results in life-long persistence of the virus in a latent form. HCMV is known to be transferred by blood products, bone marrow, and solid organs, but the cell type that carries the latent infection has been difficult to identify. We have recently demonstrated reactivation of latent HCMV in allogeneically stimulated monocyte-derived macrophages (Allo-MDM). Reactivation occurred only in macrophages produced by allogeneic but not mitogenic stimulation. The presence of dendritic cell markers on some Allo-MDM cells suggested that these macrophages were related to dendritic cells. However, dendritic cells obtained by stimulation of monocytes with interleukin-4 (IL-4) and granulocyte-macrophage colony stimulating factor (GM-CSF) were not permissive for HCMV infection. The cellular and cytokine components which are essential for HCMV replication and reactivation of virus were also examined in Allo-MDM. The importance of both CD4- or CD8-positive T cells in the generation of HCMV permissive Allo-MDM was demonstrated by negative selection or blocking experiments using antibodies directed against both HLA class I and HLA class II molecules. Examination of the cytokines essential for the generation of HCMV permissive Allo-MDM identified gamma-interferon (IFN-gamma, but not IL-1, IL-2, tumor necrosis factor alpha, or GM-CSF as critical components in the generation of these macrophages. However, addition of IFN-gamma to unstimulated macrophage cultures was insufficient to reactivate virus. These results indicate the importance of a specific moncyte stimulus in the generation of a unique HCMV permissive macrophage phenotype as well as why virus is commonly reactivated in transplant patients.
Collapse
Affiliation(s)
- C Söderberg-Nauclér
- Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland, Oregon, 97201, USA
| | | | | |
Collapse
|
21
|
Kullberg BJ, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. RESEARCH IN IMMUNOLOGY 1998; 149:478-88; discussion 515. [PMID: 9720965 DOI: 10.1016/s0923-2494(98)80771-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
22
|
Mandanas RA, Saez RA, Selby GB, Confer DL. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy. Am J Hematol 1996; 51:104-11. [PMID: 8579049 DOI: 10.1002/(sici)1096-8652(199602)51:2<104::aid-ajh2>3.0.co;2-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Forty-two cytomegalovirus (CMV)-seropositive allogeneic marrow transplant patients or recipients of CMV-seropositive marrow allografts were entered into a surveillance program to detect and treat CMV infection during the first 120 days posttransplant. CMV infection was detected at a mean time of day 50 in 21/37 (58%) patients who had surveillance cultures. Twelve of 42 (28%) received preemptive ganciclovir treatment for virus isolated from blood (9 patients) or from bronchoalveolar lavage fluid (3 patients), and all had no CMV-associated sequelae. CMV disease was diagnosed in 5 patients (4 with pneumonia), 1 with gastroenteritis) who did not have positive cultures until the onset of their disease. CMV-related mortality was 4/42 (10%). Patients who earlier manifested lung injury or diffuse alveolar hemorrhage (DAH) were significantly predisposed to subsequent CMV pneumonia (P = 0.0013, Fisher's exact test) at a median onset of day 42. Restricted prophylactic use of ganciclovir in such patients may be indicated. Fifty percent of all patients never required ganciclovir during the surveillance period. When compared to a universal prophylaxis program of ganciclovir for the prevention of CMV disease, the use of ganciclovir in a preemptive strategy could avoid unnecessary therapy for a substantial number of patients and earn significant cost-savings.
Collapse
Affiliation(s)
- R A Mandanas
- Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
| | | | | | | |
Collapse
|
23
|
Xu D, Yonetani M, Uetani Y, Nakamura H. Acquired cytomegalovirus infection and blood transfusion in preterm infants. ACTA PAEDIATRICA JAPONICA : OVERSEAS EDITION 1995; 37:444-9. [PMID: 7572143 DOI: 10.1111/j.1442-200x.1995.tb03353.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The urinary excretion of cytomegalovirus (CMV) DNA, amplified by polymerase chain reaction using two pairs of primers for late antigen (LA) and major immediate-early antigen (MIE), and serum CMV IgM were examined in 85 pre-term infants (birth-weight less than 2000 g) on admission and monthly until 6 months after birth. Of these 85 infants, 27 had blood exchange transfusions (BET) and 28 had bolus blood transfusions two to nine times. Fifteen of 27 infants underwent BET with blood that had been filtered through Pall RC100 leukocyte removal filter; the other 12 with unfiltered blood. Neither urinary CMV DNA nor serum CMV-specific IgM was detected at birth in any of the 85 pre-term infants; during the first 6 months after birth urinary CMV DNA, for both MIE and LA, appeared in 22 of the 85 infants (25.9%) and CMV IgM was positive in 14 of the 85 (16.5%). Nine of the 12 (75%) infants who received BET of unfiltered blood showed a significantly higher prevalence of urinary CMV DNA compared to the infants in the other three groups (i.e., those who received no blood transfusion, those who had bolus blood transfusions, or those who received BET of filtered blood; P < 0.01 in each instance). In a logistic regression model, CMV DNA urinary excretion was significantly associated with the mode of blood transfusion (unfiltered BET), and the Odds ratio was 38.9 (95% confidence interval, 9.4-160). There was no significant association with other independent variables such as gender, mother's seropositivity, gestational age, birth-weight or delivery mode.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D Xu
- Department of Pediatrics, Kobe University School of Medicine, Japan
| | | | | | | |
Collapse
|
24
|
Saarinen UM, Hovi L, Vilinikka L, Juvonen E, Myllylä G. Reemphasis on leukocyte transfusions: induction of myeloid marrow recovery in critically ill neutropenic children with cancer. Vox Sang 1995; 68:90-9. [PMID: 7762227 DOI: 10.1111/j.1423-0410.1995.tb02559.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Neutropenia is the major factor predisposing to sepsis in cancer patients, and its duration is important for survival. We administered leukocyte transfusions (LT) to 10 children suffering from documented life-threatening infections during profound, prolonged neutropenia. Nine had acute leukemia, and one had aplastic anemia; three were bone marrow transplant recipients. These 10 were the only patients in our unit who received LT during the past 7 years. The median leukocyte dose was 0.6 x 10(9)/kg in total. Instead of leukapheresis products, we used pooled buffy coats from random donors, with a high relative content of lymphocytes and especially T lymphocytes. The leukocyte concentrates were irradiated with 15 Gy. In all 10 patients, we observed prompt and sustained myeloid marrow recovery following LT. Such an effect of LT has never been described before. We hypothesize that in the internal milieu of these aplastic patients the transfused leukocytes were stimulated to secrete cytokines, the result being a cascade-like phenomenon and stimulation and proliferation of the patient's own bone marrow cells. The bone marrow-stimulating effect of LT merits further study.
Collapse
Affiliation(s)
- U M Saarinen
- Children's Hospital, University of Helsinki, Finland
| | | | | | | | | |
Collapse
|
25
|
Spanos T, Ladis V, Karageorga M, Theodori H, Tzivaras A, Peristeri J, Kattamis C. [Clinical evaluation of various preventive methods for non-hemolytic transfusion reactions]. Transfus Clin Biol 1995; 2:373-80. [PMID: 8581180 DOI: 10.1016/s1246-7820(05)80081-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A study has been carried out on the incidence of non-hemolytic transfusion reaction on a group of patients suffering from thalassemia. Of this group, the rate of reactions per patient, based on the relationship between the number of patients with non-hemolytic transfusion reactions and the total number had risen to 31.8%. 83.7% of the patients with non-hemolytic transfusion reactions did not give a positive reaction to lymphocytotoxicity. 654 patients having, or not having shown a non-hemolytic transfusion reaction received washed red cell concentrates prepared extemporaneously. This process allowed the rate of reaction per patient to drop to 3.9%. The transfusion of deleucocytated red cell concentrates by filtration, carried out on a group of 188 patients, made the rate of reaction per patient drop to 2.8%. As regards to rate reaction per patient, there is no significant difference statistically between these two groups, however, it must be pointed out that the administration of filtered red cell concentrates, by deleucocytation, notably improves the incidence of a feverish reaction, while the administration of washed red cell concentrates has an important impact on allergic reactions. Interestingly, in solution, the washed red cell concentrates have the added advantage of having only very small quantities of free iron or vasoactive proteic derivatives. The new four bag system, now allows us to collect, separate and wash in a closed circuit. Compared to the traditional method this system has the advantage of assuring greater efficiency and security. In conclusion, for the first time, the administration of washed red cell concentrates on patients who receive regular transfusions, may represent a good procedure, combined or not with deleucocytation by filtration, as to prevent the occurrence of non-hemolytic reactions.
Collapse
Affiliation(s)
- T Spanos
- CTS Hôpital enfants-malades, Aghia Sophia d'Athènes
| | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
The role of the blood bank in provision of an optimal granulocyte concentrate is discussed. The importance of the granulocyte dose is emphasized, and recent developments permitting the collection of larger numbers of cells are reviewed. In particular, the administration of granulocyte colony-stimulating factor to normal donors has been reported to result in dramatically increased neutrophil yields. Recent data has also suggested that increased efficiencies of collection can be realized by the use of hetastarch as the red cell sedimenting agent.
Collapse
Affiliation(s)
- T H Price
- Puget Sound Blood Center, University of Washington, Seattle, USA
| |
Collapse
|
27
|
Urushibara N, Kwon KW, Takahashi TA, Sekiguchi S. Human cytomegalovirus DNA is not detectable with nested double polymerase chain reaction in healthy blood donors. Vox Sang 1995; 68:9-14. [PMID: 7725678 DOI: 10.1111/j.1423-0410.1995.tb02537.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The PCR method was introduced to detect cytomegalovirus (CMV) DNA from 189 peripheral blood samples of volunteer donors. We adopted the nested double PCR method with primers specific for immediate early gene 1 followed by electrophoresis and ethidium bromide staining. This nested double PCR method was sensitive enough to detect approximately a single copy of CMV DNA. However, we failed to obtain positive amplification of CMV DNA from any of these donor samples. In contrast, CMV DNA could be detected in all 3 tested immunocompromised patients who had undergone bone marrow transplantation. These results support our previous report that the frequency of CMV DNA is of an order lower than 1 copy/10(5) leucocytes in the peripheral blood of healthy seropositive individuals.
Collapse
|
28
|
Stoddart CA, Cardin RD, Boname JM, Manning WC, Abenes GB, Mocarski ES. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J Virol 1994; 68:6243-53. [PMID: 8083964 PMCID: PMC237044 DOI: 10.1128/jvi.68.10.6243-6253.1994] [Citation(s) in RCA: 191] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Cytomegalovirus is transmitted with blood and organs from seropositive individuals, although the particular leukocyte population harboring latent or persistent virus remains poorly characterized. Murine cytomegalovirus, tagged with the Escherichia coli lacZ gene, was used to identify cells in which virus replicates during acute infection of immunocompetent mice. Recombinant murine cytomegaloviruses, RM461, RM460, and RM427, were constructed to express beta-galactosidase under control of the human cytomegalovirus ie1/ie2 promoter/enhancer. The lacZ gene was inserted between the ie2 and sgg1 genes in RM461 and RM460, disrupting a 0.85-kb late transcript that was found to be dispensable for replication in cultured cells as well as for infection of mice. In BALB/c mice, lacZ-tagged and wild-type viruses exhibited a similar 50% lethal dose and all had the capacity to latently infect the spleen. Peripheral blood mononuclear phagocytes were the major infected leukocyte cell type, as demonstrated by the ability of infected cells to adhere to glass and to phagocytize latex beads; however, these cells did not exhibit typical monocyte markers. Plaque assay for virus and 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) staining of frozen sections of organs from infected mice revealed that the major target organs included the spleen, adrenal glands, liver, and salivary glands, although tissues as diverse as brown fat and lungs were also involved. Individual blue-staining cells were readily identified in all infected tissues. These studies identified a mononuclear phagocyte, possibly a macrophage or dendritic cell precursor, as the vehicle of virus dissemination during acute infection, and demonstrate the utility of using lacZ-tagged murine cytomegalovirus for tropism, pathogenesis, and latency studies.
Collapse
Affiliation(s)
- C A Stoddart
- Department of Microbiology and Immunology, Stanford University School of Medicine, California 94305-5402
| | | | | | | | | | | |
Collapse
|
29
|
Söderberg C, Larsson S, Bergstedt-Lindqvist S, Möller E. Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol 1993; 67:3166-75. [PMID: 7684461 PMCID: PMC237655 DOI: 10.1128/jvi.67.6.3166-3175.1993] [Citation(s) in RCA: 99] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The identity of cells responsible for transmission of human cytomegalovirus (HCMV) in blood products or bone marrow transplants is unknown. We have tested the capacity of HCMV to in vitro infect human peripheral blood mononuclear cells (PBMC) from healthy donors and found that certain PBMC are permissive to HCMV infection. In vitro-infected viable cells were double stained for surface expression of different HMCV proteins and for cell-type-specific antigens to allow the identification of sensitive cells. All analysis were performed on viable cells, using HCMV-specific monoclonal antibodies and automated flow cytofluorimetry. PBMC were infected either with the laboratory-adapted HCMV strain AD169 or with a virus isolate obtained from a viremic patient. Up to 25% of all PBMC could express the major immediate-early antigen as well as the pp65 antigen, known at the lower matrix protein. Infected cells were mainly CD14+ monocytes, but also a small population of large CD8+ cells were susceptible to HCMV infection. CD19+ B lymphocytes were resistant to HCMV infection. Different populations of infected cells were enriched by using Dynabeads coated with cell-type-specific antibodies, and the presence of infectious virus was demonstrated by incubating the selected and sonicated cell material on human fibroblasts. Only material from infected monocytes and from CD3+ CD8+ cells gave rise to HCMV-specific plaques. The presence of HCMV mRNA as a sign of active viral transcription of the major immediate-early and late pp150 genes in infected cells was demonstrated by using nested reversed polymerase chain reaction. A common denominator was found for all cells that could be infected with HCMV. The CD13 antigen, a 130- to 150-kDa integral membrane protein identical to the enzyme aminopeptidase N, was expressed on all HCMV-permissive cells.
Collapse
MESH Headings
- Antigens, CD/immunology
- Antigens, CD19
- Antigens, Differentiation, B-Lymphocyte/immunology
- Antigens, Differentiation, Myelomonocytic/immunology
- B-Lymphocyte Subsets/immunology
- B-Lymphocyte Subsets/microbiology
- Base Sequence
- CD13 Antigens
- CD8 Antigens/immunology
- Cell Separation
- Cytomegalovirus/growth & development
- Cytomegalovirus Infections/microbiology
- Genetic Variation
- Humans
- Immunity, Innate
- Leukocytes, Mononuclear/immunology
- Leukocytes, Mononuclear/microbiology
- Lipopolysaccharide Receptors
- Molecular Sequence Data
- Monocytes/immunology
- Monocytes/microbiology
- Receptors, Virus
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/microbiology
- Transcription, Genetic
Collapse
Affiliation(s)
- C Söderberg
- Department of Clinical Immunology, NOVUM, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|
30
|
|
31
|
Affiliation(s)
- P A Pizzo
- Pediatric Branch, National Cancer Institute, Bethesda, MD 20892
| |
Collapse
|
32
|
Di Bartolomeo P, Olioso P, Papalinetti G, Bavaro P, Di Girolamo G, Angrilli F, Accorsi P, Quaglietta A, D'Antonio D, Piergallini A, Dell'isola M, Angelini A, Ciancarelli M, Fioritoni G, Iacone A, Torlontano G. The Role of Hemapheresis Technology in Allogeneic Bone Marrow Transplantation. Int J Artif Organs 1993. [DOI: 10.1177/039139889301605s01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In this paper the impact of hemapheresis technology on 238 allogeneic bone marrow transplants performed in Pescara from 1982 through 1993 is described. Granulocyte transfusions were limited to patients with neutrophil level <0.2x109/L. An average of 4 units of packed red blood cells were required to maintain adequate hemoglobin levels. Patients with major ABO incompatibility showed an increased requirement of red blood cell support as compared to patients ABO-matched and ABO minor mismatched. For platelet support single-donor platelets collected on a blood-cell separator were given. A total of 1548 platelet transfusions were examined. The median number of platelet transfusions for each patient was 5. Platelet refractoriness occurred in 44% of patients. The hemorrhage related mortality was 0.9%.The advancement made in the field of hemapheresis technology, as well as the improved transplant technique, have contributed to increase the post-transplant survival from 17% in the early experience (1976-1982) to 88% in the recent years (1992-1993).
Collapse
Affiliation(s)
- P. Di Bartolomeo
- Department of Hematology and Bone Marrow Transplantation Unit, Pescara Civil Hospital, Pescara
| | - P. Olioso
- Department of Hematology and Bone Marrow Transplantation Unit, Pescara Civil Hospital, Pescara
| | - G. Papalinetti
- Department of Hematology and Bone Marrow Transplantation Unit, Pescara Civil Hospital, Pescara
| | - P. Bavaro
- Department of Hematology and Bone Marrow Transplantation Unit, Pescara Civil Hospital, Pescara
| | - G. Di Girolamo
- Department of Hematology and Bone Marrow Transplantation Unit, Pescara Civil Hospital, Pescara
| | - F. Angrilli
- Department of Hematology and Bone Marrow Transplantation Unit, Pescara Civil Hospital, Pescara
| | - P. Accorsi
- Department of Hematology and Blood Bank, Pescara Civil Hospital, Pescara
| | - A.M. Quaglietta
- Department of Hematology and Blood Bank, Pescara Civil Hospital, Pescara
| | - D. D'Antonio
- Department of Hematology and Blood Bank, Pescara Civil Hospital, Pescara
| | - A. Piergallini
- Department of Hematology and Blood Bank, Pescara Civil Hospital, Pescara
| | - M. Dell'isola
- Department of Hematology and Blood Bank, Pescara Civil Hospital, Pescara
| | - A. Angelini
- Chair of Hematology, University of Chieti, Chieti
| | - M. Ciancarelli
- Department of Hematology and Blood Bank, Pescara Civil Hospital, Pescara
| | - G. Fioritoni
- Department of Hematology and Bone Marrow Transplantation Unit, Pescara Civil Hospital, Pescara
| | - A. Iacone
- Department of Hematology and Blood Bank, Pescara Civil Hospital, Pescara
| | - G. Torlontano
- Chair of Hematology, University of Chieti, Chieti
- IRCCS, San Giovanni Rotondo, Foggia - Italy
| |
Collapse
|
33
|
Yoser SL, Forster DJ, Rao NA. Systemic viral infections and their retinal and choroidal manifestations. Surv Ophthalmol 1993; 37:313-52. [PMID: 8387231 DOI: 10.1016/0039-6257(93)90064-e] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Viruses are one of the most common causes of infections involving the posterior segment of the eye. Such infections can occur either on a congenital or an acquired basis, and may affect primarily the retina or the choroid. Congenital cytomegalovirus (CMV) and rubella infections may result in retinitis. CMV retinitis is also the most common cause of acquired viral retinitis, primarily because of the acquired immunodeficiency syndrome (AIDS). Other types of viral retinitis, such as those caused by herpes simplex or herpes zoster, can occur in immunocompromised or immunocompetent individuals. Retinitis or choroiditis caused by viruses such as measles, influenza, Epstein-Barr virus, and Rift Valley fever virus, typically occurs subsequent to an acute viral systemic illness. The systemic and ocular manifestations, as well as the histopathology, laboratory tests, differential diagnoses, and treatment regimens for each of the individual viruses are discussed in detail.
Collapse
Affiliation(s)
- S L Yoser
- Doheny Eye Institute, University of Southern California School of Medicine, Los Angeles
| | | | | |
Collapse
|
34
|
|
35
|
Keefe KS, Freeman WR, Peterson TJ, Wiley CA, Crapotta J, Quiceno JI, Listhaus AD. Atypical healing of cytomegalovirus retinitis. Significance of persistent border opacification. Ophthalmology 1992; 99:1377-84. [PMID: 1328980 DOI: 10.1016/s0161-6420(92)31804-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
PURPOSE To analyze a phenomenon seen in patients with acquired immune deficiency syndrome (AIDS) with cytomegalovirus (CMV) retinitis undergoing systemic antiviral treatment: a persistent white border opacification on the edge of healed CMV retinitis. PATIENTS AND METHODS The authors prospectively evaluated a population of 137 patients with AIDS and CMV retinitis during a 44-month period. Eleven patients (12 eyes) who were undergoing maintenance antiviral treatment were identified with an atypical healing response--the persistence of a white flat border opacification that did not advance for many weeks to months. Patient records and photographs were reviewed. Results of one autopsy were analyzed with histopathology and special stains. RESULTS The persistent white edge maintained (without advancement or smoldering) for an average of 11.6 weeks (range, 4 to 41 weeks). This border opacification was not affected by reinduction treatment in the six patients to whom reinduction was given. Results from histopathologic examination of one patient with a persistent white border are presented: these results show that dead cytomegalic cells formed stable structures within the retina, causing white opacification that could be confused with active lesions. Immunoperoxidase stains identified CMV antigens. CONCLUSION This persistent white border opacification, which does not advance or smolder, represents an important clinical entity that should be recognized during antiviral treatment for CMV retinitis. It can often be observed. If it is not recognized as a stable configuration, patients may undergo unnecessary reinductions with potentially toxic doses of antiviral medications.
Collapse
Affiliation(s)
- K S Keefe
- Department of Ophthalmology, United States Navy Hospital, San Diego
| | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Tobias JD, Schleien C. Granulocyte transfusions--a review for the intensive care physician. Anaesth Intensive Care 1991; 19:512-20. [PMID: 1750630 DOI: 10.1177/0310057x9101900404] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In order to achieve the maximum therapeutic benefit in the treatment of malignancies, doses of chemotherapeutic agents are pushed to the point of severe marrow toxicity. This aggressive therapy can lead to iatrogenic complications including haemorrhage and sepsis due to the depletion of platelets and granulocytes. Prior to the advent of platelet transfusions, haemorrhage was the leading cause of death in these patients. Advances in blood banking and the availability of platelet transfusions have markedly decreased the incidence of fatal haemorrhage. As a result, infection has become the leading cause of death in patients with marrow failure. Although the risk of infection in patients with neutropenia has been well documented, the role of granulocyte transfusions in the treatment and prevention of these infections remains controversial. This paper will attempt to review the currently available literature regarding granulocyte procurement techniques and the efficacy of granulocyte transfusions.
Collapse
Affiliation(s)
- J D Tobias
- Division of Paediatric Anesthesiology, Vanderbilt University, Nashville, TN 37232
| | | |
Collapse
|
38
|
Andreu G, Marinière AM, Fretz C, Emile JF, Bierling P, Brossard Y, Girard M, Gluckman E, Huart JJ, Janot C. [Post-transfusional cytomegalovirus infections: incidence and methods of prevention. CMV group of SNTS]. REVUE FRANCAISE DE TRANSFUSION ET D'HEMOBIOLOGIE : BULLETIN DE LA SOCIETE NATIONALE DE TRANSFUSION SANGUINE 1991; 34:213-32. [PMID: 1648357 DOI: 10.1016/s1140-4639(05)80067-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
39
|
Affiliation(s)
- J E Gootenberg
- Department of Pediatrics, Georgetown University School of Medicine, Washington, DC
| | | |
Collapse
|
40
|
Jehn U. New antiviral drugs for treatment of viral infections in immunocompromised patients. Recent Results Cancer Res 1991; 121:353-9. [PMID: 1857874 DOI: 10.1007/978-3-642-84138-5_42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- U Jehn
- Medizinische Klinik III, Ludwig-Maximilian-Universität, München, FRG
| |
Collapse
|
41
|
Nimer SD, Champlin RE. Therapeutic use of hematopoietic growth factors in bone marrow transplantation. Cancer Treat Res 1990; 50:141-64. [PMID: 1976348 DOI: 10.1007/978-1-4613-1493-6_9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
42
|
Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Cancer Treat Res 1990; 50:113-28. [PMID: 1976346 DOI: 10.1007/978-1-4613-1493-6_7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
43
|
Abstract
Cytomegalovirus retinitis is a frequent and serious complication of various conditions, including diseases characterized by impaired immunity, such as the acquired immunodeficiency syndrome. Due to recent advances in the treatment of cytomegalovirus retinitis, accurate diagnosis and management have become increasingly important. In this review, the authors present the epidemiology, clinical features, diagnostic testing, treatment with complications, and prognosis of cytomegalovirus retinitis. A differential diagnosis is presented and the characteristic ocular lesions are illustrated.
Collapse
Affiliation(s)
- H L Hennis
- Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston
| | | | | |
Collapse
|
44
|
Fan-Havard P, Nahata MC, Brady MT. Ganciclovir--a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections. J Clin Pharm Ther 1989; 14:329-40. [PMID: 2555373 DOI: 10.1111/j.1365-2710.1989.tb00256.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
45
|
|
46
|
Affiliation(s)
- R H Herzig
- Division of Hematology/Oncology, University of Louisville, School of Medicine, Kentucky 40292
| |
Collapse
|
47
|
Affiliation(s)
- S P Adler
- Department of Pediatrics, Medical College of Virginia, Richmond
| |
Collapse
|
48
|
Champlin RE, Ho WG, Winston DJ. Acute graft-vs.-host disease and interstitial pneumonitis interrelated problems following allogeneic bone marrow transplantation: effects of intravenous immune globulin and other interventions. J Hosp Infect 1988; 12 Suppl D:29-33. [PMID: 2902126 DOI: 10.1016/0195-6701(88)90027-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- R E Champlin
- Transplantation Biology Program, UCLA Center for Health Sciences
| | | | | |
Collapse
|
49
|
|
50
|
Davis D, Henslee PJ, Markesbery WR. Fatal adenovirus meningoencephalitis in a bone marrow transplant patient. Ann Neurol 1988; 23:385-9. [PMID: 2837977 DOI: 10.1002/ana.410230412] [Citation(s) in RCA: 82] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
We describe a bone marrow transplant patient with fatal subacute adenovirus meningoencephalitis, the first such patient reported. Neuropathological examination revealed unique, bilaterally symmetrical degeneration in the inferomedial temporal cortex, amygdaloid nuclei, hippocampi, hypothalamus, and some brainstem nuclei. Viral intranuclear inclusions were noted in these areas by light microscopy and confirmed by electron microscopy. Identification was authenticated by viral culture and the isolation of adenovirus from cerebral cortical tissues, and further confirmed by immunofluorescence and serological methods.
Collapse
Affiliation(s)
- D Davis
- Department of Pathology, University of Kentucky, Lexington 40536
| | | | | |
Collapse
|